SAN DIEGO --(BUSINESS WIRE)--Jan. 12, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular testing to provide physicians with clinically actionable information to improve patient outcomes, announces that President and CEO Michael W.
Focus on new market segments and strategies to drive growth SAN DIEGO , Feb. 20, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients
SAN DIEGO , July 11, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept "), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today provided an
SAN DIEGO , April 28, 2016 /PRNewswire/ -- Biocept, Inc. (" Biocept ") (Nasdaq: BIOC) today announced a proposed registered public offering of its common stock and warrants, subject to market and other conditions. The offering is subject to market and other conditions, and there can be no assurance
Company has received more than 570,000 samples since launching its COVID-19 testing services in 2020 for skilled nursing homes, businesses, college campuses, health care facilities, and other venues SAN DIEGO --(BUSINESS WIRE)--Sep. 22, 2021-- Biocept, Inc .
SAN DIEGO , June 25, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
Expands patent protection for liquid biopsy platform SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (Nasdaq: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer, today announced receipt of a U.S.